Clinical Trials Logo

Rhinosinusitis Chronic clinical trials

View clinical trials related to Rhinosinusitis Chronic.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06105346 Not yet recruiting - Long COVID Clinical Trials

Prevalence of ENT Diseseas

PrENT
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the present study will be to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of long-COVID symptoms and further, to evaluate different factors that influence on the one hand the prevalence (urban-bred, non-urban-bred) and on the other hand symptoms (ENT-surgeries in medical history). Further, we want to evaluate if there is a correlation between subjective symptoms and apparated-based diagnostic investigations. Therefore, questionnaires and data of medical examinations, aquired routinely at the military induction board, will be analysed.

NCT ID: NCT05923047 Not yet recruiting - Clinical trials for Rhinosinusitis Chronic

Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.

MELYSA
Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

This randomized, controlled multicenter trial will recruit patients aged 18 to 70 7 years with recurrent nasal polyposis requiring surgery and indication for biologic treatment according to EPOS 2020 guideline. Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment. All study procedures will be performed in five study visits and may take approximately 30 minutes. Clinical assessments include different questionnaires and nasal endoscopy. This trial includes three treatment arms. 1. Combined group (In-office nasal polypectomy group with mepolizumab): This group will undergone in-office nasal polypectomy and will receive Mepolizumab. 2. Medical group (mepolizumab): This group will receive Mepolizumab. 3. Surgical group (In-office nasal polypectomy): This group will undergone in-office nasal polypectomy. The main advantage is that it allows comparison of mepolizumab versus surgery and surgery/mepolizumab versus surgery + mepolizumab, providing more information on the most effective therapeutic approach. The presence of adverse effects will be assessed in each treatment arm.

NCT ID: NCT05836935 Not yet recruiting - Rhinosinusitis Clinical Trials

Role of Imaging in Complications of Sinusitis

Start date: May 2023
Phase: N/A
Study type: Interventional

This study aims to assess the diagnostic performance of CT and MRI in the diagnosis of complications of rhinosinusitis in comparison to clinical and operative findings.

NCT ID: NCT05167552 Not yet recruiting - Allergic Rhinitis Clinical Trials

Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells

Start date: March 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of patients with allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells